Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

RATIONALE: A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising trea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Control Release
Main Authors: Deken, Marion M., Kijanka, Marta M., Hernández, Irati Beltrán, Slooter, Maxime D., de Bruijn, Henriette S., van Diest, Paul J., van Bergen en Henegouwen, Paul M.P., Lowik, Clemens W.G.M., Robinson, Dominic J., Vahrmeijer, Alexander L., Oliveira, Sabrina
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://ncbi.nlm.nih.gov/pubmed/32330574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2020.04.030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados